Ranked by reported Q1 2026 13F market value
Share of total reported institutional value in INDP held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | CITADEL ADVISORS LLC | 39K | $71K | β | 2.228% | 0.00% |
| 2 | GEODE CAPITAL MANAGEMENT, LLC | 27K | $49K | β | 1.542% | 0.00% |
| 3 | MORGAN STANLEY | 3K | $5K | β | 0.154% | 0.00% |
| 4 | Tower Research Capital LLC (TRC) | 2K | $3K | -40.0% | 0.108% | 0.00% |
| 5 | SBI Securities Co., Ltd. | 17 | $31 | 0.0% | 0.001% | 0.00% |
| 6 | CWM, LLC | 2 | $4 | β | 0.000% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). β% of Fundβ shows how much of that investorβs total 13F portfolio is invested in INDP β a direct measure of their conviction.
Filings activity in INDP during Q1 2026, grouped by how each filer changed its position.
No institutions added to their position this quarter.
8 quarters of 13F filings Β· Ξ columns show change vs prior quarter
| Quarter | Inst. Holders | Ξ Holders | Ownership % | Ξ Ownership | Total 13F Value | Ξ Value |
|---|---|---|---|---|---|---|
| Q1 2026 | 6 | +20% | 2.05% | +0.17 pp | $0M | +9.2% |
| Q4 2025 | 5 | +0.0% | 1.88% | +1.83 pp | $0M | +3829% |
| Q3 2025 | 5 | 17% | 0.05% | +0.00 pp | $0M | 7.3% |
| Q2 2025 | 6 | 67% | 0.05% | 5.48 pp | $0M | 99% |
| Q1 2025 | 18 | 10% | 5.53% | 3.08 pp | $0M | 36% |
| Q4 2024 | 20 | +11% | 8.61% | 3.36 pp | $1M | 28% |
| Q3 2024 | 18 | 18% | 11.97% | 8.17 pp | $1M | 41% |
| Q2 2024 | 22 | β | 20.14% | β | $1M | β |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Ξ columns compare to the immediately prior filed quarter.
Quick answers to the most common questions about buying INDP stock.
Based on Q1 2026 13F filings, institutional ownership of Indaptus Therapeutics, Inc. stands at 2.1%, held across 6 reporting institutions.
CITADEL ADVISORS LLC is the largest reported institutional holder of INDP, with approximately 39,018 shares worth $0.00B as of Q1 2026.
Yes β 1 widely-followed marquee investor appear among the top 25 institutional holders of INDP, including CITADEL ADVISORS LLC.
Our composite Smart Money Score for INDP is 51 out of 100 (Neutral). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
4 institutions opened new positions in INDP during Q1 2026, while 3 fully exited. 0 added to existing positions and 2 trimmed.
INDP institutional ownership rose by 0.17 percentage points quarter-over-quarter, with a net change of +1 holders.
The top 10 institutions account for 100.0% of all reported 13F value in INDP, and the top 25 account for 100.0%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Indaptus Therapeutics, Inc. (INDP) Institutional Ownership